Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
- PMID: 19022191
- DOI: 10.1016/S1473-3099(08)70279-2
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Abstract
Institutional outbreaks caused by Acinetobacter baumannii strains that have acquired multiple mechanisms of antimicrobial drug resistance constitute a growing public-health problem. Because of complex epidemiology, infection control of these outbreaks is difficult to attain. Identification of potential common sources of an outbreak, through surveillance cultures and epidemiological typing studies, can aid in the implementation of specific control measures. Adherence to a series of infection control methods including strict environmental cleaning, effective sterilisation of reusable medical equipment, attention to proper hand hygiene practices, and use of contact precautions, together with appropriate administrative guidance and support, are required for the containment of an outbreak. Effective antibiotic treatment of A baumannii infections, such as ventilator-associated pneumonia and bloodstream infections, is also of paramount importance. Carbapenems have long been regarded as the agents of choice, but resistance rates have risen substantially in some areas. Sulbactam has been successfully used in the treatment of serious A baumannii infections; however, the activity of this agent against carbapenem-resistant isolates is decreasing. Polymyxins show reliable antimicrobial activity against A baumannii isolates. Available clinical reports, although consisting of small-sized studies, support their effectiveness and mitigate previous concerns for toxicity. Minocycline, and particularly its derivative, tigecycline, have shown high antimicrobial activity against A baumannii, though relevant clinical evidence is still scarce. Several issues regarding the optimum therapeutic choices for multidrug-resistant A baumannii infections need to be clarified by future research.
Comment in
-
Acinetobacter baumannii infections in children.Lancet Infect Dis. 2010 Mar;10(3):143-4. doi: 10.1016/S1473-3099(10)70030-X. Lancet Infect Dis. 2010. PMID: 20185091 No abstract available.
Similar articles
-
Treatment of Acinetobacter infections.Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350. Expert Opin Pharmacother. 2010. PMID: 20210684 Review.
-
Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.J Hosp Infect. 2009 Jul;72(3):234-42. doi: 10.1016/j.jhin.2009.03.023. Epub 2009 Jun 3. J Hosp Infect. 2009. PMID: 19493588
-
Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.Clin Infect Dis. 2008 Apr 15;46(8):1254-63. doi: 10.1086/529198. Clin Infect Dis. 2008. PMID: 18444865 Review.
-
Infection Control Programs and Antibiotic Control Programs to Limit Transmission of Multi-Drug Resistant Acinetobacter baumannii Infections: Evolution of Old Problems and New Challenges for Institutes.Int J Environ Res Public Health. 2015 Jul 30;12(8):8871-82. doi: 10.3390/ijerph120808871. Int J Environ Res Public Health. 2015. PMID: 26264006 Free PMC article. Review.
-
Drug treatment for multidrug-resistant Acinetobacter baumannii infections.Future Microbiol. 2008 Dec;3(6):649-60. doi: 10.2217/17460913.3.6.649. Future Microbiol. 2008. PMID: 19072182 Review.
Cited by
-
Development of Different Methods for Preparing Acinetobacter baumannii Outer Membrane Vesicles Vaccine: Impact of Preparation Method on Protective Efficacy.Front Immunol. 2020 Jun 23;11:1069. doi: 10.3389/fimmu.2020.01069. eCollection 2020. Front Immunol. 2020. PMID: 32655550 Free PMC article.
-
Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.Antimicrob Agents Chemother. 2015 May;59(5):2720-5. doi: 10.1128/AAC.04110-14. Epub 2015 Feb 23. Antimicrob Agents Chemother. 2015. PMID: 25712362 Free PMC article.
-
Postoperative infection caused by Acinetobacter baumannii misdiagnosed as a free-living amoeba species in a humeral head hemiarthroplasty patient: a case report.Infect Dis Poverty. 2018 Mar 31;7(1):33. doi: 10.1186/s40249-018-0408-5. Infect Dis Poverty. 2018. PMID: 29631621 Free PMC article.
-
Successful control of resistance in Pseudomonas aeruginosa using antibiotic stewardship and infection control programs at a Chinese university hospital: a 6-year prospective study.Infect Drug Resist. 2018 May 1;11:637-646. doi: 10.2147/IDR.S163853. eCollection 2018. Infect Drug Resist. 2018. PMID: 29750044 Free PMC article.
-
Identifying Risk Factors for Healthcare-Associated Infections Caused by Carbapenem-Resistant Acinetobacter baumannii in a Neonatal Intensive Care Unit.Sultan Qaboos Univ Med J. 2018 Feb;18(1):e75-e80. doi: 10.18295/squmj.2018.18.01.012. Epub 2018 Apr 4. Sultan Qaboos Univ Med J. 2018. PMID: 29666685 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical